EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Editorial: Integrated PK/PD and drug metabolism approaches in drug development and evaluation

Fenglei Huang, Yurong Lai, André Dallmann, Xinning Yang

Frontiers in Pharmacology · 18.08.2026 · 17

DOI: 10.3389/fphar.2026.1941847 ↗

Kurz gefasst

Editorial in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.08.2026. Verfasst von Fenglei Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AIPBPKQSPdrug metabolismmodelingpharmacodynamicspharmacokinetics

Autor:innen und Institutionen

  • Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
  • Drug Metabolism, Gilead Sciences Inc., Foster City, CA, United States.
  • Model-Informed Drug Development, Bayer Healthcare SAS, Lille, France.
  • US Food and Drug Administration, Silver Spring, MD, United States.

Zitieren

APA

Huang, F., Lai, Y., Dallmann, A., & Yang, X. (2026). Editorial: Integrated PK/PD and drug metabolism approaches in drug development and evaluation. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1941847

Vancouver

Huang F, Lai Y, Dallmann A, Yang X. Editorial: Integrated PK/PD and drug metabolism approaches in drug development and evaluation. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1941847

BibTeX
@article{Huang2026,
  author = {Huang, Fenglei and Lai, Yurong and Dallmann, André and Yang, Xinning},
  title = {Editorial: Integrated PK/PD and drug metabolism approaches in drug development and evaluation},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1941847}
}
Kostenlos starten →